Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Upsher-Smith Snaps Up Migraine Assets As Dr Reddy’s Hones Focus

Executive Summary

Upsher-Smith has acquired US and other territory rights to two specialty product assets of Dr Reddy’s, which appears to be tweaking the commercialization approach of its proprietary products business.

You may also be interested in...



2019 India Deals - Sell, License, Brands And China

Scrip highlights the key transactions involving Indian firms in 2019. Divestments and licensing were among the prominent themes that dotted the deal landscape in the year gone by.

One-Offs Lift Dr Reddy’s In Q2

One-offs aided Dr Reddy’s performance in the second quarter although US growth was flat amid challenges including the recall of ranitidine. But the Indian firm is enthused about fresh potential opportunities for generic Suboxone in the US in view of Indivior’s intent to discontinue its authorized generic.

One-offs Lift Dr Reddy’s In Q2, Eyes Gx Suboxone Opportunities

One-offs aided Dr Reddy’s performance in the second quarter although US growth was flat amid challenges including the recall of ranitidine. But the Indian firm is enthused about fresh potential opportunities for generic Suboxone in the US in view of Indivior’s intent to discontinue its authorized generic.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC125394

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel